Effect of Ocrelizumab on B- and T-Cell Receptor Repertoire Diversity in Patients With Relapsing Multiple Sclerosis From the Randomized Phase III OPERA Trial

BACKGROUND AND OBJECTIVES: The B cell–depleting anti-CD20 antibody ocrelizumab (OCR) effectively reduces MS disease activity and slows disability progression. Given the role of B cells as antigen-presenting cells, the primary goal of this study was to evaluate the effect of OCR on the T-cell recepto...

Descripción completa

Detalles Bibliográficos
Autores principales: Laurent, Sarah A., Strauli, Nicolas B., Eggers, Erica L., Wu, Hao, Michel, Brady, Demuth, Stanislas, Palanichamy, Arumugam, Wilson, Michael R., Sirota, Marina, Hernandez, Ryan D., Cree, Bruce Anthony Campbell, Herman, Ann E., von Büdingen, H.-Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136682/
https://www.ncbi.nlm.nih.gov/pubmed/37094998
http://dx.doi.org/10.1212/NXI.0000000000200118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136682/
https://www.ncbi.nlm.nih.gov/pubmed/37094998
http://dx.doi.org/10.1212/NXI.0000000000200118

Ejemplares similares